Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation by the copolymer glatiramer acetate.

Ruth Arnon1, Michael Sela

  • 1Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel. ruth.arnon@weizmann.ac.il

Journal of Molecular Recognition : JMR
|January 21, 2004
PubMed
Summary

Glatiramer acetate (GA) effectively treats multiple sclerosis (MS) by inducing immune tolerance. Clinical trials show GA reduces relapses and disability in RRMS patients, offering a well-tolerated first-line therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair.

Pharmacological reviews·2024
Same author

Repurposing of glatiramer acetate to treat cardiac ischemia in rodent models.

Nature cardiovascular research·2024
Same author

Amyloid Precursor Protein and Tau Peptides Linked Together Ameliorate Loss of Cognition in an Alzheimer's Disease Animal Model.

International journal of molecular sciences·2023
Same author

Prof. Michael Sela (1924-2022).

European journal of immunology·2022
Same author

Role of Helical Structure in MBP Immunodominant Peptides for Efficient IgM Antibody Recognition in Multiple Sclerosis.

Frontiers in chemistry·2022
Same author

Neuroprotective Effect of Glatiramer Acetate on Neurofilament Light Chain Leakage and Glutamate Excess in an Animal Model of Multiple Sclerosis.

International journal of molecular sciences·2021

Area of Science:

  • Neuroimmunology
  • Autoimmune Diseases
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Experimental Autoimmune Encephalitis (EAE) serves as a key animal model for MS.
  • Glatiramer acetate (GA), a synthetic copolymer, is investigated for its immunomodulatory properties.

Purpose of the Study:

  • To evaluate the efficacy and mechanism of action of Glatiramer acetate (GA) in experimental autoimmune encephalitis (EAE) and multiple sclerosis (MS).
  • To assess GA's safety and tolerability profile in comparison to other MS therapies.

Main Methods:

  • GA's suppressive activity in EAE models was studied, focusing on immunological cross-reactivity with myelin basic protein (MBP).
  • GA's mechanism of action involving binding to MHC class II molecules and induction of Th2-type suppressor T cells was investigated.

Related Experiment Videos

  • Phase II and III clinical trials were conducted in relapsing-remitting MS (RRMS) patients.

    • Main Results:

    • GA demonstrated significant suppression of EAE in various animal models.
    • Clinical trials confirmed GA's efficacy in reducing relapse rates, MRI-assessed disease activity, and disability progression in RRMS patients.
    • GA exhibited a favorable safety profile, with fewer side effects compared to beta-interferons.

    Conclusions:

    • Glatiramer acetate (GA) is a highly effective immunomodulatory therapy for RRMS.
    • GA's mechanism involves inducing antigen-specific suppressor cells and modulating T-cell responses.
    • GA is a valuable and well-tolerated first-line treatment option for patients with relapsing-remitting MS.